As of 2025-03-16, the EV/EBITDA ratio of Cue Biopharma Inc (CUE) is -0.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CUE's latest enterprise value is 33.49 mil USD. CUE's TTM EBITDA according to its financial statements is -45.22 mil USD. Dividing these 2 quantities gives us the above CUE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 13.3x | 12.2x |
| Forward P/E multiples | 17.3x - 34.9x | 21.6x |
| Fair Price | (11.91) - (9.05) | (11.64) |
| Upside | -1344.4% - -1046.0% | -1316.0% |
| Date | EV/EBITDA |
| 2025-03-13 | -0.76 |
| 2025-03-12 | -0.81 |
| 2025-03-11 | -0.86 |
| 2025-03-10 | -0.84 |
| 2025-03-07 | -0.94 |
| 2025-03-06 | -0.90 |
| 2025-03-05 | -0.97 |
| 2025-03-04 | -1.04 |
| 2025-03-03 | -1.08 |
| 2025-02-28 | -1.12 |
| 2025-02-27 | -1.14 |
| 2025-02-26 | -1.24 |
| 2025-02-25 | -1.15 |
| 2025-02-24 | -1.18 |
| 2025-02-21 | -1.25 |
| 2025-02-20 | -1.32 |
| 2025-02-19 | -1.40 |
| 2025-02-18 | -1.33 |
| 2025-02-14 | -1.49 |
| 2025-02-13 | -1.39 |
| 2025-02-12 | -1.26 |
| 2025-02-11 | -1.18 |
| 2025-02-10 | -1.26 |
| 2025-02-07 | -1.19 |
| 2025-02-06 | -1.29 |
| 2025-02-05 | -1.39 |
| 2025-02-04 | -1.38 |
| 2025-02-03 | -1.38 |
| 2025-01-31 | -1.43 |
| 2025-01-30 | -1.31 |
| 2025-01-29 | -1.28 |
| 2025-01-28 | -1.28 |
| 2025-01-27 | -1.33 |
| 2025-01-24 | -1.49 |
| 2025-01-23 | -1.35 |
| 2025-01-22 | -1.10 |
| 2025-01-21 | -1.10 |
| 2025-01-17 | -1.24 |
| 2025-01-16 | -1.19 |
| 2025-01-15 | -1.21 |
| 2025-01-14 | -1.11 |
| 2025-01-13 | -1.28 |
| 2025-01-10 | -1.52 |
| 2025-01-08 | -1.43 |
| 2025-01-07 | -1.64 |
| 2025-01-06 | -1.85 |
| 2025-01-03 | -1.35 |
| 2025-01-02 | -0.93 |
| 2024-12-31 | -0.93 |
| 2024-12-30 | -0.83 |